Welcome to our dedicated page for NVTA news (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on NVTA stock.
This page aggregates news and press releases related to Invitae (OTC: NVTA), a medical genetics company that focuses on clinical genetic testing, variant classification, and genomic data research. The news coverage reflects Invitaes role in medical laboratories, health care, and social assistance, as well as its corporate and financial developments.
Company announcements describe Invitae as a provider of genetic information that aims to deliver accurate and actionable results to support medical decision-making. News items include updates on research presented at professional meetings, such as the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting and the American Society of Breast Surgeons Annual Meeting. These stories highlight work on variant reclassification, machine learning models for hereditary cancer and Lynch syndrome genes, and studies of variants of uncertain significance and their impact on clinical management.
Other articles focus on Invitaes technology platforms and data resources, including the Invitae Generation platform and Clinical Variant Modeling, which the company describes as using machine learning and large genomic datasets to improve variant classification. News also covers collaborations with biopharmaceutical partners, such as an agreement with BridgeBio Pharma to use Invitaes rare disease enriched dataset and analytical capabilities for genetics-based drug discovery.
In addition to scientific and product-related updates, the news feed includes major corporate events. These include Invitaes filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey, its court-supervised sale process, and the selection of Labcorp as the winning bidder to acquire substantially all of the companys assets, subject to approvals. Asset transactions involving specific business lines, such as the transfer of certain reproductive health assets to Natera, also appear in coverage.
Investors, clinicians, and others interested in NVTA can use this page to review historical and ongoing developments in Invitaes research activities, technology initiatives, partnerships, restructuring efforts, and asset sales as reported in public news sources.
Invitae Corporation (NYSE: NVTA) announced the grant of restricted stock units (RSUs) to its new Chief Operating Officer, Kenneth D. Knight, and Chief Digital Officer, Karthik Suri. A total of 475,000 shares were allocated under the 2015 Stock Incentive Plan for inducement awards, in compliance with NYSE Rule 303A.08. Knight received 250,000 RSUs, and Suri received 150,000 RSUs, both subject to vesting conditions over several years. The grants aim to incentivize key personnel to enhance company performance.
Invitae Corporation (NYSE: NVTA) reported its Q2 2020 results, revealing a recovery despite pandemic disruptions. Total revenue was $46.2 million, down from $53.5 million in Q2 2019. The company accessioned over 120,000 samples, an increase from last year, but gross profit fell significantly to $3.2 million compared to $25.5 million in the same quarter last year. Net loss widened to $166.4 million, or $1.29 per share. Cash and equivalents totaled $428.5 million. The company aims to enhance its offerings through acquisitions and increased telehealth services, positioning itself for future growth.
Invitae Corporation (NYSE: NVTA) has announced it will report its second quarter 2020 financial results on August 4, 2020. A conference call and webcast are scheduled for that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the financial results and recent highlights. Interested participants can register online or by phone to access the call. Invitae aims to integrate comprehensive genetic information into mainstream medicine, enhancing healthcare for billions of people. For further details, visit invitae.com.
Invitae (NYSE: NVTA) has announced a definitive agreement to acquire ArcherDX, creating a leader in cancer genetics and precision oncology. This strategic combination aims to enhance patient care through integrated diagnostic testing and therapy optimization services. The deal, valued at approximately $1.4 billion, involves 30 million shares and $325 million in cash upfront, with additional shares based on milestones. Financing commitments have reached over $400 million, supporting Invitae's continued innovation in genetics. The merger is expected to close in several months, pending approval.